Introduction
Valproic acid (VPA) is widely used to treat multiple conditions, such as epilepsy, migraine, and bipolar disorder. However, it has been reported that the incidence of abnormally elevated serum ammonia level varies from 16.2% to 52.3% during VPA-based therapy [1] , and that the underlying mechanism responsible for this increased plasma ammonia level is unclear. The factors known to cause an increase in the plasma ammonia level include the VPA daily dose [2] , the duration of VPA treatment [3, 4] , and the additional use of antiepileptic drugs [5] . Previously, we reported that VPA daily dose, gender, and phenytoin and/or phenobarbital and/or topiramate coadministration are strongly linked with exceeding 150 mg/dL as a plasma ammonia level during VPAbased therapy, based upon a large-scale examination intended for Japanese pediatric patients having epilepsy [6] .
A link has been suggested between a genetic polymorphism (4217C>A) in the gene encoding mitochondrial carbamoylphosphate synthase 1 (CPS1) and severe hypreammonemia (plasma ammonia level 3 200 mg/dL) during VPA-based therapy in pediatric patients having epilepsy [7] . The CPS1 enzyme, a component of the urea cycle, transfers ammonia from the amide group of glutamine to a molecule of bicarbonate, consuming ATP and producing carbamoyl-phosphate in the process [8] . However, we found that phenytoin coadministration and not CPS1 4217C>A polymorphism was strongly related to exceeding the plasma ammonia level of 200 mg/dL during VPA-based therapy in our previous examination of 177 Japanese pediatric patients having epilepsy [9] .
Ammonia is also consumed by glutamine synthetase, in addition to the urea cycle. The enzymatic activity of glutamine synthetase, which is widely expressed in the liver, brain, gastrointestinal tract, and peripheral lymphocyte [10] , decreases on phenytoin administration [11] . Polymorphisms have also been identified in the glutamine synthetase gene (GLUL). We selected three single nucleotide polymorphisms (rs10911021, rs10911070, and rs10797771) in GLUL gene. Because the rs10911021 polymorphism, which is located at 3 0 untranslated region of the GLUL gene, has been associated with the enzymatic activity of glutamine synthetase [12] . In this study, the GLUL rs10911021 polymorphism was associated with an elevated the risk of coronary heart disease in type 2 diabetes. As compared to T allele homozygotes in the GLUL rs10911021 polymorphism, the expression of the GLUL gene in a C allele homozygote was decreased by 32% in human endothelial cells. Arai et al. examined the association between 6 GLUL polymorphisms and schizophrenia susceptibility and reported no significant differences [13] . From these 6 GLUL polymorphisms, we selected the rs10911070 and rs10797771 polymorphisms located in the upstream region, which may also affect the enzymatic activity of glutamine synthetase.
This study was designed to examine the influence of patient characteristics (age, gender, body weight, VPA concentration, VPA daily doses, adjusted VPA concentration, number of antiepileptic drugs, and concomitant antiepileptic drug use) and GLUL polymorphisms (rs10911070, rs10797771, and rs10911021) on the development of hyperammonemia in 202 Japanese pediatric patients having epilepsy. Hyperammonemia was defined using two different cutoff values in this study: a plasma ammonia levels exceeding 200 mg/dL and 170 mg/dL. These levels were chosen because plasma ammonia concentrations exceeding 200 mg/dL are known to cause severe coma and respiratory failure leading to lifethreatening conditions [14] , and concentrations greater than 170 mg/dL (100 mmol/L) are associated with neurological symptoms [15] .
Materials and methods

Patients
This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the Ethics Committee of the Shizuoka Institute of Epilepsy and Neurological Disorders and the University of Shizuoka, Shizuoka, Japan. From January 2006 to December 2013, we enrolled 202 Japanese patients having pediatric epilepsy (age, 0-15 years) who were being treated with VPA and undergoing blood ammonia measurements. This is a retrospective study and the study population included both inpatients and outpatients at the Shizuoka Institute of Epilepsy and Neurological Disorders. A portion of the subjects participated in our previous study [9] , and the others were newly recruited subjects. Written informed consent was obtained from each subject or their guardian after a detailed briefing of the study purposes and protocols. We obtained blood samples for the analysis of GLUL polymorphisms from each patient and retrospectively reviewed electronic medical records for patient characteristics, age, gender, body weight, plasma ammonia level, liver function, concomitant antiepileptic drugs, VPA daily dose, and VPA concentration. Potential subjects who showed noncompliance with therapy, those with severe hepatic or renal dysfunction (aspartate aminotransferase or alanine aminotransferase > 500 U/L and/or serum creatinine > 3.0 mg/dL), those on a ketogenic diet, and those with intercurrent infection were excluded.
Measurement of plasma ammonia levels and VPA concentration
Blood samples were drawn from each subject into a heparinized tube, which was placed on ice as soon as possible after collection. The plasma ammonia level was promptly measured using a bromophenol blue colorimetric test conducted with a VITROS5600 autoanalyzer system (Ortho Clinical Diagnostics, Tokyo, Japan). A separate blood sample obtained at the same time was used for measuring the VPA concentration. This sample was centrifuged at 3000 rpm, after which the VPA concentration was measured with a latex immunoagglutination assay using the same autoanalyzer. With respect to blood ammonia level, we selected the highest value in each patient during VPA treatment.
Genotyping procedures
Peripheral blood was drawn from subjects using ethylenediaminetetraacetic acid (EDTA)-2Na Venoject II tubes (Terumo, Tokyo, Japan). Genomic DNA was isolated from these blood samples by using a MagNA Pure Compact System (Roche Diagnostics, Mannheim, Germany). The genotypes of three GLUL polymorphisms (rs10911021, rs10911070, and rs10797771) were determined using a newly established polymerase chain reactionrestriction fragment length polymorphism -(PCR-RFLP) based method. The scheme is shown in Table 1 . In brief, genomic DNA (100 ng) was amplified in the PCR buffer containing dNTP mixture (200 mM), forward primer (1 mM), and reverse primer (1 mM), HotStar Taq plus DNA polymerase (1.25 units; Qiagen, Tokyo, Japan), and MgCl 2 (1.5 mM). Amplification was performed using an i-Cycler thermal cycler (Bio-Rad, Tokyo, Japan). PCR comprised an initial denaturation/enzyme activation step at 95 8C for 5 min, amplification for 35 cycles at 94 8C for 30 s, an appropriate Table 1 Three gltamate synthetase (GLUL) genetic polymorphisms and primers of PCRs, and corresponding resriction enzymes. annealing temperature for 30 s, treatment at 72 8C for 30 s and a final extension step at 72 8C for 10 min. PCR products were digested with each restriction enzyme (New England BioLab, Beverly, MA, USA) according to the manufacturer's instructions (Table 1) . Digested products were separated by electrophoresis on a 4% agarose gel, and the genotype was assigned based on the results of the analysis of the digestion patterns. The accuracy of this PCR-RFLP-based method was confirmed by direct sequencing of the amplified PCR product.
Statistical analysis
Derivation of the genotyping data from the Hardy-Weinberg equilibrium was assessed using the chi-square test for goodness-of fit. A 2-tailed chi square test or 2-tailed Fisher's exact test was used to compare quantitative variables (age, gender, body weight, VPA concentration, VPA daily doses, adjusted VPA concentration, the number of antiepileptic drugs, concomitant antiepileptic drugs, and three GLUL polymorphisms) between patients with or without the development of hyperammonemia in a univariate analysis. For age, body weight, VPA concentration, VPA daily doses, adjusted VPA concentration, and the number of antiepileptic drugs used, 2 groups were established based on the median value of each endpoint. The variables that showed a moderate relationship (p < 0.15) with the development of hyperammonemia in a univariate analysis were included in the multivariate logistic regression analysis. The final model was built using the stepwise method (p < 0.05). All statistical analyses were performed using SPSS ver.18.0 software (IBM, Tokyo, Japan). Statistical differences at p < 0.05 were considered to be significant.
Results
Patient characteristics and VPA therapy
Patient characteristics are presented in Table 2 . The number of patients that developed hyperammonemia during VPA-based therapy was 20 (9.9%) using the 200 mg/dL cutoff value and 30 (14.9%) using the 170 mg/dL cutoff value. The distributions of the three GLUL polymorphisms were not significantly different from those predicted using the Hardy-Weinberg equilibrium. Substantial fractions of the patients received dual (77, 38.1%) or triple (74, 37.1%) antiepileptic drug therapies, including VPA. The drug most often combined with VPA was clobazam, followed by phenytoin and zonisamide.
Association between patient variables and the development of hyperammonemia
We evaluated each potential risk factor for the development of hyperammonemia using a univariate analysis (Table 2 ). These analyses revealed that age, phenytoin coadministration, and GLUL rs10797771 polymorphism showed p values <0.15 using the 200 mg/dL cutoff value, while age, gender, body weight, number of antiepileptic drugs, phenytoin coadministration, acetazolamide coadministration, nitrazepam coadministration, and GLUL rs10797771 polymorphism showed p values < 0.15 using the 170 mg/dL cutoff value. We subjected these variables to a multivariate logistic regression analysis performed using the stepwise method (Table 3 ). This analysis revealed that phenytoin coadministration (p < 0.001) and having the C allele in the GLUL rs10797771 polymorphism (p = 0.044) were risk factors for exceeding a plasma ammonia level of 200 mg/dL during VPAbased therapy. The odds ratios of phenytoin coadministration and having the C allele in the GLUL rs10797771 polymorphism were 5.919 [95% confidence interval (95% CI), 2.220-15.780] and 2.817 (95% CI, 1.028-7.718), respectively. Age was not included in the stepwise multivariate logistic regression analysis because it had a p-value of >0.05 in the stepwise multivariate logistic regression analysis.
In contrast, phenytoin coadministration (p < 0.001), having the C allele in the GLUL rs10797771 polymorphism (p = 0.013), and female gender (p = 0.037) were the risk factors for exceeding a plasma ammonia level of 170 mg/dL during VPA-based therapy.
Nitrazepam coadministration had a p-value of <0.05 and was included in the stepwise multivariate logistic regression analysis, but was not significantly different. The odds ratios of phenytoin coadministration, having the C allele in the GLUL rs10797771 polymorphism, and female gender were 7.635 (95%CI, 3.077-18.944), 3.151 (95% CI, 1.279-7.761), and 2.653 (95% CI, 1.059-6.650), respectively. Age, body weight, number of antiepileptic drugs, and acetazolamide coadministration were not included in the stepwise multivariate logistic regression analysis because these 4 variables had p-values of >0.05 in the stepwise multivariate logistic regression analysis.
Discussion
The incidence (9.9%) of exceeding 200 mg/dL as a plasma ammonia level during VPA-based therapy in the present study was higher than those (2.3 and 6.3%) in previous reports [6, 7] . The percentage of patients receiving VPA monotherapy in our study may have been lower than that of the two previous reports because concomitant antiepileptic drug use has been suggested as one of the factors contributing to elevation of the plasma ammonia level during VPA-based therapy [5] . In this study, we also provided the incidence of exceeding a plasma ammonia level of 170 mg/dL (100 mmol/L) during VPA-based therapy among pediatric patients having epilepsy. There were only case reports about the association between plasma ammonia levels expressed in mmol/L. There were some reports stating that the hyperammonemia was defined as plasma ammonia level of 100 mmol/L (=170 mg/dL) outside VPAbased therapy [15, 16] . However, although this level has been associated with neurological symptoms [17] , there was no report about the incidents of exceeding a plasma ammonia level of 170 mg/dL during VPA-based therapy. Tseng et al. reported that 6 of 44 patients showing plasma ammonia levels of more than 93 mg/dL during VPA-based therapy presented with nausea, fatigue, ataxia, and consciousness disturbance [18] . In this study, we did not examine clinical symptoms associated with hyperammonemia development because they were not included in the electronic medical records in detail. Further studies are necessary to investigate the association between clinical symptoms and elevated plasma ammonia levels.
We found that the GLUL rs10797771 polymorphism added to phenytoin coadministration was a risk factor for the development of severe hyperammonemia, with a plasma ammonia level exceeding 200 mg/dL. In our previous studies, phenytoin coadministration was the strongest risk factor for the development of hyperammonemia [6, 9] . The administration of phenytoin induces the expression of drug metabolic enzymes, such as cytochrome P450s and UDP-glucuronosyl transferases [19] which metabolize VPA to 2-propyl-4-pentenoic acid, propionate, VPA-glucuronide, and so on [20, 21] . VPA metabolites, such as 2-propyl-4-pentenoic acid and propionate, have been observed to potentiate the VPAassociated accumulation of ammonia [22] . In this study, we did not examine the association between the concentrations of these VPA metabolites and plasma ammonia levels. Future studies are warranted to investigate the correlation between the concentration of these VPA metabolites and plasma ammonia levels.
In this study, we found that the GLUL rs107997771 polymorphism is a novel risk factor for the development of severe hyperammonemia during VPA-based therapy. As for GLUL polymorphisms, patients having the C allele in the GLUL rs10797771 polymorphism easily exceeded a plasma ammonia level of 200 mg/dL during VPA-based therapy. GLUL rs10797771 is located 165 bp upstream of the transcription start site (National Center for Biotechnology Information reference sequence; NG_013347). The association between the GLUL rs10797771 polymorphism and the enzymatic activity of glutamine synthetase remains unclear. Furthermore, it was known that there are other polymorphisms in GLUL gene. It has been reported that the enzymatic activity of glutamine synthetase is decreased by phenytoin administration in mouse brain [11] , and that the expression of glutamine synthetase in glioblastoma patients having epilepsy is lower than in those without epilepsy [23] . Glutamine synthetase is expressed in the liver, brain, gastrointestinal tract, and peripheral lymphocytes [10] , while the urea cycle functions only in the liver. If the plasma ammonia level increases during liver failure, glutamine synthetase becomes the key enzyme in ammonia clearance. In our opinion, it is necessary to investigate the possible association between the development of hyperammonemia and activity of glutamine synthetase, including the effects of this or other GLUL polymorphisms and/or phenytoin coadministration. Female gender was also found to be a risk factor for exceeding a plasma ammonia level of 170 mg/dL during VPA-based therapy. In this study, female patients had a significantly higher mean VPA daily dose than male patients (male vs. [24] . However, the median daily dose of VPA in both males and females was lower than 30 mg/kg/day in this study. Furthermore, we did not find the association between the daily dose of VPA and the development of hyperammonemia in the univariate analysis (p < 0.15). Pleym et al. suggested that UDP-glucuronosyl transferase activity is higher in males than in females, suggesting that cytochrome P450-derived metabolites are more important in females [25] . Cytochrome P450s converts VPA to its hepatotoxic metabolites, such as 2-propyl-4-pentenoic acid [20, 22] . Gender-based differences of UDP-glucuronosyl transferase activity presumably account for the differences in VPA metabolism and ammonia levels.
In conclusion, phenytoin coadministration, GLUL rs10797771 polymorphism in the 200 mg/dL cutoff value, and female in addition to two factors in the 170 mg/dL cutoff value, are independent risk factors for elevated plasma ammonia levels during VPA-based therapy.
